Issue 2/2009
Content (12 Articles)
Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R)
Milica Pešić, Tijana Andjelković, Jasna Banković, Ivanka D. Marković, Ljubiša Rakić, Sabera Ruždijić
Suppressive effects of novel derivatives prepared from Aconitum alkaloids on tumor growth
Masaharu Hazawa, Koji Wada, Kenji Takahashi, Takao Mori, Norio Kawahara, Ikuo Kashiwakura
Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer
Manon Buijs, Josephina A. Vossen, Jean-Francois H. Geschwind, Takayoshi Ishimori, James M. Engles, Obele Acha-Ngwodo, Richard L. Wahl, Mustafa Vali
In vitro cytotoxic activity of tri-n-butyltin(IV)lupinylsulfide hydrogen fumarate (IST-FS 35) and preliminary antitumor activity in vivo
Angela Alama, Maurizio Viale, Michele Cilli, Cristina Bruzzo, Federica Novelli, Bruno Tasso, Fabio Sparatore
Synthesis and antiproliferative activity of substituted diazaspiro hydantoins: a structure–activity relationship study
Ananda Kumar C. S., S. B. Benaka Prasad, K. Vinaya, S. Chandrappa, N. R. Thimmegowda, S. R. Ranganatha, Sanjay Swarup, K. S. Rangappa
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820
Ron J. Keizer, Miren K. Zamacona, Mendel Jansen, David Critchley, Jantien Wanders, Jos H. Beijnen, Jan H. M. Schellens, Alwin D. R. Huitema
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies
H. Sayar, Z. Shen, S. J. Lee, M. Royce, I. Rabinowitz, F. Lee, H. Smith, S. Eberhardt, A. Maestas, H. Lu, C. Verschraegen
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer
Elaina M. Gartner, Kent A. Griffith, Quintin Pan, George J. Brewer, Gwen F. Henja, Sofia D. Merajver, Mark M. Zalupski
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)
G. Schilling, M. Bruweleit, N. Harbeck, C. Thomssen, K. Becker, R. Hoffmann, C. Villena, M. Schütte, D. K. Hossfeld, C. Bokemeyer, M. de Wit
Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients
Noor Al-Dasooqi, Joanne M. Bowen, Rachel J. Gibson, Thomas Sullivan, Jude Lees, Dorothy M. Keefe
Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer
Giuseppe Gullo, Daniela Bettio, Valter Torri, Giovanna Masci, Piermario Salvini, Armando Santoro
Bowel perforation in non-small cell lung cancer after bevacizumab therapy
Elisabeth Schellhaas, Christoph Loddenkemper, Alexander Schmittel, Heinz-J. Buhr, Uwe Pohlen